Navigation Links
NuVasive to Present at ThinkEquity Partners 5th Annual Growth Conference
Date:9/13/2007

SAN DIEGO, Sept. 13 /PRNewswire-FirstCall/ -- NuVasive, Inc. (Nasdaq: NUVA), a medical device company focused on developing products for minimally disruptive surgical treatments for the spine, announced today that Keith Valentine, President and Chief Operating Officer, and Kevin O'Boyle, Executive Vice President and Chief Financial Officer, are scheduled to present at the ThinkEquity Partners 5th Annual Growth Conference at the St. Regis Hotel, in San Francisco, CA on Monday, September 17, 2007 at 9:00 a.m. PT.

A live Web cast of the presentation will be available online from the investor relations page of the Company's corporate Web site at http://www.nuvasive.com. After the live Web cast, the presentation will remain available on NuVasive's Web site, http://www.nuvasive.com, for 30 days.

About NuVasive

NuVasive is a medical device company focused on the design, development and marketing of products for the surgical treatment of spine disorders. The Company's product portfolio is focused on applications in the over $3.6 billion U.S. spine fusion market. The Company's current principal product offering includes a minimally disruptive surgical platform called Maximum Access Surgery, or MAS(TM), as well as a growing offering of cervical and motion preservation products.

The MAS platform offers advantages for both patients and surgeons such as reduced surgery and hospitalization time and faster recovery. MAS combines three categories of current product offerings: NeuroVision(R) a proprietary software-driven nerve avoidance system; MaXcess(R) a unique split-blade design retraction system; and specialized implants, like SpheRx(R) and CoRoent(R), that collectively minimize soft tissue disruption during spine surgery while allowing maximum visualization and surgical reproducibility. NuVasive's product offering is also focused on cervical in
'/>"/>

SOURCE NuVasive, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Surgeons Presented Guidelines For Postoperative Atrial Fibrillation
2. Researchers Present Ways To Reduce The Risk Of Dementia
3. Researchers Present Data Regarding The Efficiency Of Herbs
4. Critically Ill Patients More At Risk Of Infection If Glucose Is Present In Their Lung Secretions
5. Ovarian Cancer Presents ‘Target Symptoms’ Six Months Before Diagnosi
6. Drug Reactions First Present Themselves In The Mouth
7. Reminiscing Into The Past Makes You Dissatisfied With The Present
8. Living In The Past Indicates Dissatisfaction With Present
9. Movies Represent Coma In A Wrong Way
10. Onchocerciasis: Presentation And Treatment
11. Researchers Warn That Routine Physical Examination Could Miss Breech Presentation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/8/2009)...udy released this week showing that a growing numb...c diseases shines a much-needed spotlight on the n...at focuses on primary and secondary prevention, ac... disease prevention. , , (Logo: http://www...., , The study, conducted by Social & Scient...
(Date:1/8/2009)...chle at his confirmation hearing to be the next Se...SHINGTON, Jan. 8 Bipart...ator Tom Daschle, nominee for Department of Health...ellow BPC founder and friend Senator Bob Dole at h...vened by the Senate Health, Education, Labor, and ...
(Date:1/8/2009)...earch Hospital have demonstrated a more effective ...nza. They found that the antibiotics clindamycin a... their protein synthesis, are more effective than ...tam" antibiotic ampicillin, which causes the bacte...ant because pneumonia, rather than the influenza i...
(Date:1/8/2009)...re-FirstCall/ -- Medivation, Inc.,(Nasdaq: MDVN...t and chief,executive officer, will present at th...n Wednesday, January 14, at 10:00 a.m. Pacific Tim...o. , Dr. Hung will provide an overview of M...or Dimebon for Alzheimer,s and Huntington,s diseas...
Breaking Medicine News(10 mins):Health News:U.S. Preventive Medicine: Chronic Disease Study Demonstrates Need for Focus on Primary and Secondary Prevention 2Health News:Bipartisan Policy Center Founding Board Members Daschle and Dole Appear on Capitol Hill 2Health News:Bipartisan Policy Center Founding Board Members Daschle and Dole Appear on Capitol Hill 3Health News:Bipartisan Policy Center Founding Board Members Daschle and Dole Appear on Capitol Hill 4Health News:Study finds more effective treatment for pneumonia following influenza 2Health News:Study finds more effective treatment for pneumonia following influenza 3Health News:Medivation Announces Participation in 27th Annual J.P. Morgan Healthcare Conference 2
...ine has been shrouded in controversy. Now, Britain...alled for an end to the raging //debates over this...public that warns of a threat to young lives by fo...They have appealed to the politicians, healthcare ...
...lison, a University of Alabama biostatistician has...ons for obesity. //He was assisted in this venture...da and Italy. The researchers looked at more than... besides exercise and diet. They found that the fo...
... is on the rise in New Zealand. Hence Pharmac deci...se who have serious fluctuations in blood sugar le...r Lantus at a subsidized rate from July 1. Murra... the Diabetes New Zealand said that they have work...
...rays of women with high-risk genes could increase ...archers led by David Goldgar // at the Internation...d 1,600 women. He found that women with BRCA1 and ... mutations who had undergone a chest X-ray were 54...
Other Medicine News:
(Date:1/8/2009)...EUVEN, Belgium, January 9 /PRNewswire-FirstCall/ -...died in the Treatment of,Vitreomacular Adhesion i...onext Brussels: THR), a biotechnology company,foc...cular disease and,cancer, announces today that it...croplasmin for the non-surgical treatment of back ...
(Date:1/8/2009)...HICAGO, Jan. 8 If you are taking p... you,re not alone. Half of the people taking,pres... reasons are,varied -- they forget, are busy with...ot to. Noncompliance has been called the Achilles ...ral Everett Koop commented, "Drugs don,t,work in ...
(Date:1/7/2009)...NDIANAPOLIS, Jan. 7 Eli ...that it received a complete response letter from,...anzapine long-acting,injection (LAI) for acute an...s. Lilly is continuing to work with the agency on ...does not require any additional clinical trials fo...
(Date:1/7/2009)...RICK, Md., Jan. 7 ImQuest Life Sci... an IND application to the Food and Drug Administr...lead pyrimidinedione HIV inhibitor IQP-0410. ImQue... the first quarter of 2009. IQP-0410 is a novel sm... as a nonnucleoside reverse transcriptase inhibito...
Breaking Medicine Technology:ThromboGenics Begins Phase III Program With Microplasmin for the Non-surgical Treatment of Back of the Eye Disease 2ThromboGenics Begins Phase III Program With Microplasmin for the Non-surgical Treatment of Back of the Eye Disease 3ThromboGenics Begins Phase III Program With Microplasmin for the Non-surgical Treatment of Back of the Eye Disease 4Good Medicine: Smarter Smartphones for People With Chronic Disease 2FDA Issues a Complete Response Letter for Lilly's Olanzapine LAI for Treatment of Schizophrenia in Adults 2FDA Issues a Complete Response Letter for Lilly's Olanzapine LAI for Treatment of Schizophrenia in Adults 3FDA Issues a Complete Response Letter for Lilly's Olanzapine LAI for Treatment of Schizophrenia in Adults 4FDA Issues a Complete Response Letter for Lilly's Olanzapine LAI for Treatment of Schizophrenia in Adults 5FDA Issues a Complete Response Letter for Lilly's Olanzapine LAI for Treatment of Schizophrenia in Adults 6ImQuest Submits Investigational New Product Application to the Food and Drug Administration to Initiate HIV Therapeutic Clinical Trials with IQP-0410 2Delaware Man Spearheads Brain Tumor Awareness 7970 1Delaware Man Spearheads Brain Tumor Awareness 7970 2Medical Device Producers Express Interest in Purolator USA 26apos 3Bs Express Service and Customer Service 26868 1Medical Device Producers Express Interest in Purolator USA 26apos 3Bs Express Service and Customer Service 26868 2New Trend of Healthcare Companies Sending Patients Abroad for Surgery is Dangerous Says James Goldberg Whose Son Died Following Surgery in Thailand 26863 1New Trend of Healthcare Companies Sending Patients Abroad for Surgery is Dangerous Says James Goldberg Whose Son Died Following Surgery in Thailand 26863 2Never Events Responsible for One Out of Six Med Mal Liability Claims Says Aon 26859 1Never Events Responsible for One Out of Six Med Mal Liability Claims Says Aon 26859 2Never Events Responsible for One Out of Six Med Mal Liability Claims Says Aon 26859 3Never Events Responsible for One Out of Six Med Mal Liability Claims Says Aon 26859 4Never Events Responsible for One Out of Six Med Mal Liability Claims Says Aon 26859 5
...abasis Therapeutics,Inc. (Nasdaq:MBRX), a biophar...opment and commercialization of novel drugs for th...lying unique,capabilities for targeting the liver ...rs were presented at the Endocrine Society,s,89th ...rovide data on MB07811, the Company,s,liver-target...
...able to two widely used diabetes medicines , , ...n 33,000 type 2 diabetes patients in a real-world,... the incidence of,hospitaliations for heart attack...rization for patients on Avandia is the,same as ...ere,released in a paper titled “Coronary Hea...
Other Medicine Technology:Metabasis Therapeutics Presents Results of Preclinical Studies for,MB07811, Its Novel Product Candidate for the Treatment of,Hyperlipidemia, at the Endocrine Society's Annual Meeting 2Metabasis Therapeutics Presents Results of Preclinical Studies for,MB07811, Its Novel Product Candidate for the Treatment of,Hyperlipidemia, at the Endocrine Society's Annual Meeting 3Metabasis Therapeutics Presents Results of Preclinical Studies for,MB07811, Its Novel Product Candidate for the Treatment of,Hyperlipidemia, at the Endocrine Society's Annual Meeting 4Newly Published Data from Large Study Support Cardiovascular Safety,of Avandia (Rosiglitazone Maleate) 2Newly Published Data from Large Study Support Cardiovascular Safety,of Avandia (Rosiglitazone Maleate) 3Newly Published Data from Large Study Support Cardiovascular Safety,of Avandia (Rosiglitazone Maleate) 4
Eliminating the need for any manual pipetting, the HydraPLUS delivers precise micro-volumes of sample directly from primary tubes to four HYDRASYS sample applicators contained in a built-in humidity
...ECHET EXTENDER® is a new device for skin exten... elastomer strips, it allows a constant and powerf...r devices capacities. Such effectiveness makes the...it is removed before 30 days. Furthermore it is in...
Inquire
Inquire
Medicine Products: